Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer

Oncotarget

Volumn 7, Issue 31, 2016, Pages 50490-50506

  Weidner, Philip ^a   Söhn, Michaela ^a   Gutting, Tobias ^a   Friedrich, Teresa ^a   Gaiser, Timo ^a   Magdeburg, Julia ^a   Kienle, Peter ^a   Ruh, Hermelindis ^b   Hopf, Carsten ^b   Behrens, Hans Michael ^c   Röcken, Christoph ^c   Hanoch, Tamar ^d   Seger, Rony ^d   Ebert, Matthias P A ^a   Burgermeister, Elke ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MANNHEIM UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Colorectal cancer; Insulin; MTMR7; Myotubularin; Phosphatase

Indexed keywords

BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE 1; MYOTUBULARIN RELATED PROTEIN 7; PHOSPHATIDYLINOSITIDE; PROTEIN KINASE B; SOMATOMEDIN B; UNCLASSIFIED DRUG; IGF2 PROTEIN, HUMAN; INSULIN; MTMR7 PROTEIN, HUMAN; MTMR7 PROTEIN, MOUSE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; MTMR7 GENE; MTMR9 GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR VOLUME; ANIMAL; COLORECTAL TUMOR; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GENOME IMPRINTING; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MOUSE; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TISSUE MICROARRAY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOMIC IMPRINTING; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TISSUE DISTRIBUTION;

EID: 84981347186     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10466     Document Type: Article

References (41)

1. Tebbutt N, Pedersen MW and Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013; 13: 663-673.
2. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012; 12: 159-169.
3. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-337.
4. Shi J, Xiong L, Li J, Cao H, Jiang W, Liu B, Chen X, Liu C, Liu K, Wang G and Cai K. A Linear Dose-Response Relationship between Fasting Plasma Glucose and Colorectal Cancer Risk: Systematic Review and Metaanalysis. Sci Rep. 2015; 5: 17591.
5. Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: A meta-analysis and systematic review. World J Gastroenterol. 2015; 21: 6026-6031.
6. Park J, Morley TS, Kim M, Clegg DJ and Scherer PE. Obesity and cancer-mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014; 10: 455-465.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
8. Cox AD, Fesik SW, Kimmelman AC, Luo J and Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014; 13: 828-851.
9. Mochizuki Y and Majerus PW. Characterization of myotubularin-related protein 7 and its binding partner, myotubularin-related protein 9. Proc Natl Acad Sci U S A. 2003; 100: 9768-9773.
10. Nicot AS and Laporte J. Endosomal phosphoinositides and human diseases. Traffic. 2008; 9: 1240-1249.
11. Hnia K, Vaccari I, Bolino A and Laporte J. Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology. Trends Mol Med. 2012; 18: 317-327.
12. Zou J, Zhang C, Marjanovic J, Kisseleva MV, Majerus PW and Wilson MP. Myotubularin-related protein MTMR 9 determines the enzymatic activity, substrate specificity, and role in autophagy of MTMR8. Proc Natl Acad Sci U S A. 2012; 109: 9539-9544.
13. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-404.
14. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6: pl1.
15. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483: 603-607.
16. Pole JC, Courtay-Cahen C, Garcia MJ, Blood KA, Cooke SL, Alsop AE, Tse DM, Caldas C and Edwards PA. Highresolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene. 2006; 25: 5693-5706.
17. Zhou W, Goodman SN, Galizia G, Lieto E, Ferraraccio F, Pignatelli C, Purdie CA, Piris J, Morris R, Harrison DJ, Paty PB, Culliford A, Romans KE, Montgomery EA, Choti MA, Kinzler KW and Vogelstein B. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet. 2002; 359: 219-225.
18. Shimobayashi M and Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2015; 15: 155-162.
19. Fetalvero KM, Yu Y, Goetschkes M, Liang G, Valdez RA, Gould T, Triantafellow E, Bergling S, Loureiro J, Eash J, Lin V, Porter JA, Finan PM, Walsh K, Yang Y, Mao X and Murphy LO. Defective autophagy and mTORC1 signaling in myotubularin null mice. Mol Cell Biol. 2012; 33: 98-110.
20. Razidlo GL, Katafiasz D and Taylor GS. Myotubularin regulates Akt-dependent survival signaling via phosphatidylinositol 3-phosphate. J Biol Chem. 2011; 286: 20005-20019.
21. Hao F, Itoh T, Morita E, Shirahama-Noda K, Yoshimori T and Noda T. The PtdIns3-phosphatase MTMR3 interacts with mTORC1 and suppresses its activity. FEBS Lett. 2016; 590: 161-173.
22. Mei J, Li Z and Gui JF. Cooperation of Mtmr8 with PI3K regulates actin filament modeling and muscle development in zebrafish. PLoS One. 2009; 4: e4979.
23. Guo L, Martens C, Bruno D, Porcella SF, Yamane H, Caucheteux SM, Zhu J and Paul WE. Lipid phosphatases identified by screening a mouse phosphatase shRNA library regulate T-cell differentiation and protein kinase B AKT signaling. Proc Natl Acad Sci U S A. 2013; 110: E1849-1856.
24. Al-Qusairi L, Prokic I, Amoasii L, Kretz C, Messaddeq N, Mandel JL and Laporte J. Lack of myotubularin MTM1 leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways. Faseb J. 2013; 27: 3384-3394.
25. Lawlor MW, Viola MG, Meng H, Edelstein RV, Liu F, Yan K, Luna EJ, Lerch-Gaggl A, Hoffmann RG, Pierson CR, Buj-Bello A, Lachey JL, Pearsall S, Yang L, Hillard CJ and Beggs, AH. Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1 p R69C mice. Am J Pathol. 2014; 184: 1831-1842.
26. Cao C, Backer JM, Laporte J, Bedrick EJ and Wandinger-Ness A. Sequential actions of myotubularin lipid phosphatases regulate endosomal PI 3 P and growth factor receptor trafficking. Mol Biol Cell. 2008; 19: 3334-3346.
27. De Roock W, De Vriendt V, Normanno N, Ciardiello F and Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011; 12: 594-603.
28. Lito P, Rosen N and Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013; 19: 1401-1409.
29. Chiarini F, Evangelisti C, McCubrey JA and Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci. 2015; 36: 124-135.
30. Liu R, Hu LL, Sun A, Cao YJ, Tang T, Zhang XP and Zhang QH. mRNA expression of IGF-1 and IGF-1R in patients with colorectal adenocarcinoma and type 2 diabetes. Arch Med Res. 2014; 45: 318-324.
31. Baba Y, Nosho K, Shima K, Huttenhower C, Tanaka N, Hazra A, Giovannucci EL, Fuchs CS and Ogino S. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology. 2010; 139: 1855-1864.
32. Belharazem D, Magdeburg J, Berton AK, Beissbarth L, Sauer C, Sticht C, Marx A, Hofheinz R, Post S, Kienle P and Strobel P. Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications. J Gastroenterol. 2017.
33. Shackelford DB and Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009; 9: 563-575.
34. Ingold Heppner B, Behrens HM, Balschun K, Haag J, Kruger S, Becker T and Rocken C. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014; 111: 1977-1984.
35. Burgermeister E, Xing X, Rocken C, Juhasz M, Chen J, Hiber M, Mair K, Shatz M, Liscovitch M, Schmid RM and Ebert MP. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res. 2007; 67: 8519-8526.
36. Burgermeister E, Friedrich T, Hitkova I, Regel I, Einwachter H, Zimmermann W, Rocken C, Perren A, Wright MB, Schmid RM, Seger R and Ebert MP. The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor gamma through spatial relocalization at helix 7 of its ligand-binding domain. Mol Cell Biol. 2011; 31: 3497-3510.
37. Fulop A, Porada MB, Marsching C, Blott H, Meyer B, Tambe S, Sandhoff R, Junker HD and Hopf C. 4-Phenylalpha-cyanocinnamic acid amide: screening for a negative ion matrix for MALDI-MS imaging of multiple lipid classes. Anal Chem. 2013; 85: 9156-9163.
38. Ebert MP, Tanzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day C, Rosenberg R, Reinacher-Schick AC, Schulmann K, Tannapfel A, Hofheinz R, Rocken C, Keller G, Langer R, Specht K, Porschen R, Stohlmacher-Williams J, Schuster T, Strobel P and Schmid RM. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med. 2012; 366: 44-53.
39. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: e45.
40. Boger C, Warneke VS, Behrens HM, Kalthoff H, Goodman SL, Becker T and Rocken C. Integrins alphavbeta3 and alphavbeta5 as prognostic, diagnostic, and therapeutic targets in gastric cancer. Gastric Cancer. 2015; 18: 784-795.
41. Metzger ML, Behrens HM, Boger C, Haag J, Kruger S and Rocken C. MET in gastric cancer-discarding a 10% cutoff rule. Histopathology. 2016; 68: 241-253.